Background: Metabolic syndrome (MetS) is a common comorbidity in psoriasis. However, the associations between MetS, psoriasis and mortality remain largely unclear. Objectives: To investigate the synergistic effect of MetS and psoriasis on total and cardiovascular disease (CVD) mortality in a representative sample of US adults. Methods: In total, 14 930 participants from the 2003–2006 and 2009–2014 National Health and Nutrition Examination Survey were included in this prospective, nationwide cohort study. Participants were stratified into the psoriasis−/MetS− (reference) group, psoriasis−/MetS+ group, psoriasis+/MetS− group and psoriasis+/MetS+ group. Results: Overall, 14 930 participants, 50.71% were male, with a mean age of 43 years, were included in the final analysis. The weighted percentages of participants in the psoriasis−/MetS−, psoriasis−/MetS+, psoriasis+/MetS− and psoriasis+/MetS+ groups were 72.77%, 24.36%, 1.94% and 0.93%, respectively. In total, 874 deaths (246 of which were related to CVD) occurred during a median follow-up of 110 months. Compared with the reference group, the hazard ratios in the psoriasis−/MetS+, psoriasis+/MetS− and psoriasis+/MetS+ groups were 1.788 [95% confidence interval (CI) 1.486–2.152], 0.858 (95% CI 0.431–1.707) and 2.050 (95% CI 1.028–4.092), respectively, for all-cause mortality, and 1.856 (1.350–2.552), 1.229 (95% CI 0.292–5.181) and 4.571 (95% CI 1.724–12.119), respectively, for CVD mortality. Subgroup analysis showed that this association was not influenced by participants’ age, sex, physical activity, smoking, estimated glomerular filtration rate, or urinary albumin/creatinine ratio. Similar results were obtained in the sensitivity analysis of the main results. Conclusions: Presence of comorbid MetS significantly increases all-cause and CVD mortality in patients with psoriasis. Dermatologists can potentially aid in reducing mortality rates in patients with psoriasis through targeted screening for MetS.